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Introduction
Upper gastrointestinal bleeding (UGIB) is associ-
ated with a markedly increased mortality and 
morbidity.1,2 Despite an improvement in medical 
care, UGIB is still a common gastrointestinal 
emergency with an incidence rate of 78 per 
100,000 persons annually1,3,4 and a case fatality of 
about 10 deaths per 100 patients.5,6
Risk of UGIB is known to be associated with use 
of drugs, in particular non-steroidal anti-inflam-
matory drugs (NSAIDs) and oral anticoagu-
lants.7,8 Beta-blockers have a well-documented 
protective effect on variceal bleeding in cirrhotic 
patients,9 and several observational studies have 
suggested that beta-blocker use is also protective 
against UGIB in general.10–15 However, these 
were generally small studies, resulting in impre-
cise results and further did not discriminate 
between selective and non-selective beta-blockers 
(see Supplementary Table 1).
It has been suggested that a gastro-protective 
effect of beta-blockers on UGIB might be medi-
ated through effects on the secretion of prosta-
glandins and gastrin.16–18 A decrease in the portal 
venous pressure may also influence the risk of 
UGIB, as seen in cirrhotic patients with variceal 
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bleeding.19–21 However, the exact biological mech-
anisms behind the suggested protective effect of 
beta-blockers on non-variceal UGIBs remain 
uncertain.
As beta-blockers are widely used in the treatment 
of cardiovascular disease, including hypertension, 
heart failure, myocardial infarction and stroke, a 
potential protective effect on UGIBs is important 
to uncover.22 In this large population-based case-
control study, our aim was to evaluate the sug-
gested protective effect of beta-blockers on UGIB 
and elucidate possible differences between differ-
ent types of beta-blockers.
Methods
This study was a register-based, population-based 
case-control study. We compared the use of beta-
blockers among individuals with UGIB (cases) 
with the use among individuals without UGIB 
(controls) to estimate the odds ratio (OR) for 
UGIB associated with beta-blocker use.
Data sources
Data were retrieved from three sources: the Danish 
Central Person Register (CPR), the Funen County 
Patient Administrative System (FPAS) and Odense 
Pharmaco-epidemiological Database (OPED). All 
three registers contain detailed longitudinal data at 
an individual level. The CPR covers the entire 
Danish population, while FPAS and OPED cover 
the population of Funen County (470,000 individ-
uals). All Danish citizens are assigned a unique civil 
registration number, which is used in all records 
and enables flawless linkage between registers.23,24
The CPR contains information on date of birth, 
sex, current and historic residency, migrations to 
and from Denmark and date of death.24 The data 
were used to extract controls and to ensure that 
cases and controls had permanent residence on 
Funen for at least 365 days prior to their index 
date.
FPAS holds information on hospital contact 
among Funen County residents, including dis-
charge diagnoses since 1973. Diagnoses have 
been encoded by the International Classification 
of Diseases 10th edition (ICD-10) since 1994.
OPED has information on all reimbursed drug 
dispensation from Funen County since 1990. 
Each prescription record includes, among other 
information, the substance, the date of dispensa-
tion, the formulation of the drug and quantity dis-
pensed for each prescription given by number, 
strength and defined daily dose (DDD).25,26 
Dosing instructions and indications are not 
recorded. All drugs are registered according to 
the Anatomical Therapeutical Chemical (ATC) 
index.27 All beta-blockers (ATC: C07) require a 
prescription.
The dataset has been used and described in detail 
in a previous study concerning the association 
between SSRI use and UGIB.28
Cases and controls
Our source population was the residents of Funen 
County during a study period of 1 August 1995 to 
31 July 2006. This population has been shown to 
be representative of the population in Denmark in 
general.29 We included as cases all individuals 
who fulfilled the following three criteria: (1) 
admission to a hospital in Funen County within 
the study period, with peptic ulcer or gastritis as 
the main diagnosis; (2) mention of melena, a sub-
normal hemoglobin, or the need for transfusion in 
the discharge summary or medical record; and 
(3) a potential bleed source in the stomach or 
duodenum verified by endoscopy or surgery. 
Bleedings caused by gastric varices were excluded.
All discharge summaries (n = 12,607) with a 
main diagnosis of peptic ulcer (complicated or 
not) or gastritis in the study period were manually 
reviewed in order to include cases coded under 
less specific diagnoses not indicating bleeding. 
During the review, the study group was blinded 
to the exposure status of potential cases. Each 
case was assigned an index date defined as the 
first registered date of a UGIB diagnosis.
Controls were selected by risk-set sampling strat-
egy – that is, for each case we randomly selected 
10 controls among the individuals in our source 
population who matched the case by sex and birth 
year. Controls were assigned an index date identi-
cal to the index date of the corresponding case. 
We allowed that cases could be selected as con-
trols before they had their case-defining event. 
Thereby, the calculated OR is an unbiased esti-
mate of the incidence rate ratio that would have 
emerged from a cohort study, based on the same 
source population.30
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We required that both cases and controls had 
been residents of Funen County for at least one 
year on the index date. We excluded cases and 
controls with a diagnosis of liver disease before 
their index date. Patients with liver cirrhosis use 
unselective beta-blockers as prophylaxis against 
variceal bleeding and have a strongly elevated 
risk of peptic ulcer bleeding,31 thereby constitut-
ing a potential confounder. As this exclusion was 
performed after the matching and as some of the 
very old cases had fewer than 10 eligible con-
trols, the final control:case ratio deviated slightly 
from 10:1.
Exposure
Subjects who had their latest beta-blocker pre-
scription within the past 120 days before or at 
the index date were categorized as current users. 
In Denmark, chronic medication is usually dis-
pensed in supplies of 100 days. We added a 
grace period of 20% to account for minor non-
adherence or irregular prescription filling due to 
stockpiling, thus arriving at a window of 120 
days. This assumption was validated by an 
analysis of the waiting-time distribution.32 
Individuals whose latest beta-blocker prescrip-
tion was redeemed between 240 and 120 days 
before the index date were categorized as recent 
users; individuals whose last beta-blocker pre-
scription was redeemed more than 240 days 
before the index date were categorized as past 
users. The reference for all analyses was never-
users of beta-blockers.
In supplementary analyses, beta-blockers were sub-
divided into non-selective (alprenolol, oxprenolol, 
pindolol, propranolol, timolol, sotalol, tertatolol) 
and selective (metoprolol, atenolol, acebutolol, 
betaxolol, bisoprolol). The two combined alpha- 
and beta-blockers (carvedilol and labetalol) were 
both classified as non-selective based on the profile 
of their beta-blocker action.33,34
The daily dose of beta-blockers for a treatment 
episode was calculated by dividing the cumulative 
number of DDDs dispensed for all prescriptions 
(except the last) within the episode by the num-
ber of days between the first and the last prescrip-
tion. We considered a chain of successive 
beta-blocker prescriptions to belong to the same 
treatment episode if the interval between them 
never exceeded 120 days (i.e. consistent with our 
exposure definition). For episodes consisting of 
only one beta-blocker prescription, the daily dose 
could not be calculated. The categorization of 
daily doses (0–0.49, 0.50–0.99 and ⩾1.00 DDD/
day) was based on explorative analyses of pre-
scription renewals.
Data analysis
By using conditional logistic regression, we esti-
mated the crude and adjusted ORs with 95% 
confidence intervals (CIs). Confounding by age, 
sex and calendar time was accounted for by the 
matching and conditional analysis. For the 
adjusted ORs, the following potential confound-
ers were included: (1) current use of the follow-
ing drugs: vitamin K antagonists (VKA), aspirin, 
other antiplatelet drugs, NSAIDs, selective sero-
tonin reuptake inhibitors (SSRIs), systemic corti-
costeroids, proton pump inhibitors (PPIs), H2 
receptor antagonists, statins, nitrates, spironolac-
tone, calcium antagonists, bisphosphonates; (2) 
any history of the following events: UGIB, 
Helicobacter pylori (HP) eradication, peptic ulcer, 
chronic obstructive pulmonary disease (COPD), 
diabetes, ischemic heart disease, heart failure, 
stroke, hypertension, inflammatory bowel dis-
ease, malignant disease, renal failure; and (3) 
prescription or diagnosis markers of smoking or 
excessive alcohol consumption. For all drugs, 
current drug use was defined by the filling of a 
prescription within fewer than 120 days before 
the index date.
For information on codes used to define the 
covariates, see Appendix.
Supplementary analyses
In order to appraise the influence of confounding 
by unmeasured lifestyle covariates, we performed 
a number of supplementary analyses. We esti-
mated the association between use of beta-block-
ers (all types) and UGIB within subgroups 
defined by: (1) any ulcer antecedent (i.e. no his-
tory of peptic ulcer or use of anti-ulcer drugs); (2) 
any use of NSAIDs; (3) any use of antiplatelet 
drugs; (4) a history of gastrointestinal cancer; (5) 
any markers of alcohol abuse; and (6) different 
categories of Charlson score (0, 1–2 and 3 or 
more).35 We performed the subgroup analysis 
stratified on beta-blocker class – that is, non-
selective and selective beta-blockers. Finally, we 
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performed an analysis nested within ever-users of 
antihypertensives other than beta-blockers (i.e. 
inhibitors of the renin-angiotensin system, thi-
azides and related drugs or calcium channel 
blockers). The rationale was that if the apparent 
effect of beta-blockers was explained by unmeas-
ured confounders related to the presence of 
hypertension, this particular analysis would show 
no association.
All main analyses were carried out independently 
in duplicate and found to reproduce results 
accurately.
Others
All analyses were performed using STATA 14.2 
(StataCorp, College Station, TX, USA). This 
study was approved by the Danish Data Protection 
Agency. According to Danish legislation, neither 
approval from the ethics committee nor informed 
consent from the study populations is required 
for registry-linkage studies.23
Results
We identified 3571 UGIB cases and 35,582 con-
trols. Their median age was 75 (interquartile 
range: 64–83) and 50.7% were male. All included 
comorbidities and currently used drugs were 
more common among UGIB cases than controls, 
as was the use of ulcerogenic medications (Table 
1). As an example, 34.2% of cases were classified 
as current users of NSAIDs compared with 11.3% 
of controls.
Both ever and current use of beta-blockers were 
more prevalent among cases than controls 
(26.9% versus 18.1% and 13.6% versus 9.1%, 
respectively). The crude OR for the association 
between ever-use of beta-blockers and UGIB 
was 1.70 (95% CI: 1.57–1.85). After adjust-
ment for confounding, use of beta-blockers 
was not found to be associated with risk of 
UGIB (adjusted OR 1.10; 95% CI: 1.00–1.21), 
emphasizing that the increased risk suggested in 
the crude analysis can be explained by the higher 
level of comorbidity and polypharmacy among 
cases. The association remained neutral after 
stratification by recency, daily dosage, selective 
and non-selective beta-blockers and the most 
commonly used single beta-blocker substances 
(Table 2).
The association between current beta-blocker 
use and UGIB within subgroups is illustrated in 
Table 3. Stratifying by age and sex revealed no 
association. Restricting to non-users of PPI, 
NSAIDs and antiplatelets, and by the absence of 
gastrointestinal cancers, ulcer antecedents and 
alcohol abuse likewise showed no association 
(Table 3). Similarly, we found no association 
among ever-users of antihypertensives other than 
beta-blockers. Finally, we demonstrated no asso-
ciation within subgroups with different severities 
of comorbidity assessed by the Charlson score 
(Table 3).
For all confounders adjusted for in the analyses, 
we performed a post-hoc analysis to evaluate the 
contribution from each of them. Ischemic heart 
disease was identified as having the largest contri-
bution, as the beta-blocker–UGIB estimate 
adjusted for this variable alone came closest to the 
fully adjusted value (Supplementary Table 2).
Discussion
In this population-based case-control study, we 
found no decreased risk of UGIB associated with 
beta-blocker use, neither overall nor within spe-
cific classes or types of beta-blockers. This find-
ing was consistent after stratification by recency 
and dosage, as well as within subgroups of patients 
with an increased risk of UGIB.
The association between beta-blocker use and the 
risk of gastrointestinal bleeding has previously 
been assessed in six observational studies 
(Supplementary Table 1).10–13,15,36 In a case-con-
trol study nested among new users of antihyper-
tensive agents, Suissa and colleagues found that 
use of beta-blockers decreased the risk of gastro-
intestinal bleeding (adjusted rate ratio (RR) 0.66 
(95% CI: 0.44–0.98).12 Though not statistically 
significant, the ORs from a case-control study by 
Lanas and colleagues36 supported this finding. 
Similarly, two cohort studies suggested a protec-
tive effect of beta-blockers compared with ACE 
inhibitors or calcium antagonists.11,15 A recent 
study by Nagata and colleagues10 could not sup-
port an association, but the number of exposed 
cases was very low and confidence intervals wide. 
Lastly, García Rodriguez and colleagues13 investi-
gated the association between multiple exposures, 
including beta-blocker use and verified UGIB. 
They found an increased risk of UGIB with use of 
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Table 1. Characteristics of cases and controls at the index date.
Cases
(n = 3571)
Controls 
(n = 35,582)
 All Exposed
(n = 3221)
Unexposed
(n = 29,144)
Age  
Median (IQR) 75 (64–83) 75 (64–83) 78 (71–84) 75 (62–83)
Sex  
 Men 1811 (50.7%) 18,029 (50.7%) 1502 (46.6%) 15,061 (51.7%)
Current drug use  
 VKA 183 (5.1%) 823 (2.3%) 237 (7.4%) 413 (1.4%)
 Low-dose aspirin 696 (19.5%) 3436 (9.7%) 779 (24.2%) 2109 (7.2%)
 Other antiplatelet drugs 197 (5.5%) 782 (2.2%) 168 (5.2%) 481 (1.7%)
 NSAID 1220 (34.2%) 4005 (11.3%) 453 (14.1%) 3139 (10.8%)
 SSRI 429 (12.0%) 2038 (5.7%) 215 (6.7%) 1496 (5.1%)
 Systemic corticosteroids 384 (10.8%) 1638 (4.6%) 150 (4.7%) 1295 (4.4%)
 PPI 521 (14.6%) 2037 (5.7%) 320 (9.9%) 1395 (4.8%)
 H2 receptor antagonists 294 (8.2%) 958 (2.7%) 105 (3.3%) 732 (2.5%)
 Statins 237 (6.6%) 1572 (4.4%) 520 (16.1%) 695 (2.4%)
 Nitrates 318 (8.9%) 1678 (4.7%) 497 (15.4%) 820 (2.8%)
 Spironolactone 208 (5.8%) 599 (1.7%) 110 (3.4%) 380 (1.3%)
 Calcium antagonists 588 (16.5%) 3829 (10.8%) 613 (19.0%) 2363 (8.1%)
 Bisphosphonates 70 (2.0%) 439 (1.2%) 50 (1.6%) 333 (1.1%)
History of  
 UGIB 95 (2.7%) 175 (0.5%) 18 (0.6%) 119 (0.4%)
 HP eradication 160 (4.5%) 467 (1.3%) 51 (1.6%) 331 (1.1%)
 Peptic ulcer 218 (6.1%) 535 (1.5%) 62 (1.9%) 375 (1.3%)
 COPD 256 (7.2%) 1044 (2.9%) 74 (2.3%) 834 (2.9%)
 Diabetes 404 (11.3%) 2167 (6.1%) 327 (10.2%) 1533 (5.3%)
 Ischemic heart disease 867 (24.3%) 5272 (14.8%) 1301 (40.4%) 2822 (9.7%)
 Heart failure 279 (7.8%) 1164 (3.3%) 244 (7.6%) 670 (2.3%)
 Stroke 353 (9.9%) 1835 (5.2%) 250 (7.8%) 1264 (4.3%)
 Hypertension 412 (11.5%) 1863 (5.2%) 532 (16.5%) 839 (2.9%)
 Inflammatory bowel disease 23 (0.6%) 107 (0.3%) 9 (0.3%) 87 (0.3%)
 Malignant disease 244 (6.8%) 1711 (4.8%) 213 (6.6%) 1318 (4.5%)
 Renal failure 94 (2.6%) 205 (0.6%) 45 (1.4%) 108 (0.4%)
 Alcohol-related markers 166 (4.6%) 336 (0.9%) 32 (1.0%) 271 (0.9%)
 Tobacco-related markers 1148 (32.1%) 8364 (23.5%) 778 (24.2%) 6637 (22.8%)
COPD, chronic obstructive pulmonary disease; HP, Helicobacter pylori; IQR, interquartile range; NSAID, non-steroidal 
anti-inflammatory drugs; PPI, proton pump inhibitors; SSRI, selective serotonin reuptake inhibitors; UGIB, upper 
gastrointestinal bleeding; VKA, vitamin K antagonists.
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antihypertensive agents (RR: 1.7; 95% CI: 1.4–
2.1); however, users of beta-blockers alone were 
found to have no increased risk of UGIB (RR: 
1.0; 95% CI: 0.7–1.4) (see Appendix). All of 
these studies were small, including only 4–65 
cases exposed to beta-blockers, and did not 
attempt to differentiate between selective and 
non-selective beta-blockers. In comparison, we 
included 484 exposed cases, more than twice the 
cumulative number from prior studies.
Our study has several important strengths. First 
and foremost, a manual validation of all cases was 
performed, thereby minimizing the risk of out-
come misclassification. Even admissions that did 
not specify UGIB were reviewed in order to 
capture cases that were imprecisely coded. Due to 
the high quality of our case data, we were able to 
reproduce all the well-established risk factors for 
UGIB as demonstrated in Table 1. Second, our 
approach was truly population based as Danish 
health care offers full tax-funded coverage to all 
citizens and we had access to data on their medi-
cal history since 1994 and their drug use since 
1990. It is unlikely that patients would suffer 
severe UGIB without this being captured in our 
data.
Information bias or confounding by variables not 
included in this study cannot be fully excluded. 
First, we did not have data on lifestyle factors that 
could potentially be confounders. Instead, we 
Table 2. Association between use of beta-blockers and UGIB.
Cases
(n = 3571)
Controls
(n = 35,582)
Crude odds ratio 
(95% CI)
Adjusted odds 
ratio* (95% CI)
Non-use 2610 29,121 1.00 (reference) 1.00 (reference)
Ever-use 958 6431 1.71 (1.57–1.85) 1.10 (1.00–1.21)
Beta-blocker class (current use)  
 Selective 376 2354 1.79 (1.58–2.01) 1.12 (0.97–1.30)
 Metoprolol 281 1679 1.90 (1.66–2.19) 1.15 (0.97–1.36)
 Atenolol 61 465 1.37 (1.04–1.80) 1.00 (0.74–1.37)
 Non-selective 111 886 1.39 (1.13–1.71) 0.85 (0.67–1.08)
 Propranolol 38 338 1.24 (0.88–1.75) 1.03 (0.71–1.51)
 Carvedilol 31 173 2.14 (1.43–3.21) 0.77 (0.48–1.25)
Usage  
 Current 484 3218 1.70 (1.52–1.89) 1.07 (0.94–1.21)
 Recent 60 388 1.76 (1.32–2.33) 1.25 (0.91–1.72)
 Past 414 2825 1.66 (1.48–1.86) 1.06 (0.93–1.21)
Dosage, current use (DDD/day)  
 0–0.49 140 1070 1.45 (1.20–1.74) 0.96 (0.77–1.19)
 0.5–1.0 195 1361 1.60 (1.36–1.88) 0.96 (0.79–1.16)
 >1.0 108 614 2.03 (1.63–2.52) 1.32 (1.03–1.69)
 Unknown 41 173 2.40 (1.68–3.41) 1.48 (0.98–2.23)
ASA, acetylsalicylic acid; COPD, chronic obstructive pulmonary disease; DDD: Defined daily doses; HP, Helicobacter 
pylori; NSAID, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitors; SSRI, selective serotonin reuptake 
inhibitors; UGIB, upper gastrointestinal bleeding; VKA, vitamin K antagonists.
* Adjusted for: current use of: VKA, ASA, other antiplatelet drugs, NSAID, SSRIs, systemic corticosteroids, PPIs, H2 
receptor antagonists, statins, nitrates, spironolactone, calcium antagonists, bisphosphonates; any history of: UGIB, HP 
eradication, peptic ulcer, COPD, diabetes, ischemic heart disease, heart failure, stroke, hypertension, inflammatory 
bowel disease, malignant disease, renal failure; and prescription or diagnosis markers of smoking or excessive alcohol 
consumption.
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used proxies for smoking and excessive alcohol 
use. Smoking is associated with cardiovascular 
disease and hence the use of beta-blockers. 
However, smoking is not a strong risk factor for 
peptic ulcer bleeding.37,38 Excessive drinking is a 
risk factor for peptic ulcer bleeding.39 There is no 
clinical reason to prefer beta-blockers in patients 
with high alcohol consumption, if they have not 
developed liver disease. However, if patients with 
high alcohol consumption use beta-blockers more 
often than others, this would elevate the OR and 
might conceal a true protective effect. To this end, 
we did exclude patients with liver disease as they 
represent a special subgroup with confounding 
Table 3. Association between current use of beta-blockers and UGIB within subgroups.
Subgroup Cases
exposed/
unexposed
Controls
exposed/
unexposed
Crude
odds ratio
95% CI
Adjusted *
odds ratio
95% CI
All 484/2610 3218/29,121 1.70 (1.52–1.89) 1.07 (0.94–1.21)
Sex  
 Men 226/1363 1501/15,044 1.69 (1.45–1.98) 0.97 (0.80–1.17)
 Women 258/1247 1717/14,077 1.70 (1.47–1.98) 1.16 (0.97–1.38)
Age (years)  
 <55 34/350 120/4053 3.23 (2.16–4.83) 1.04 (0.54–1.99)
 55–75 207/962 1125/11,172 2.14 (1.81–2.52) 1.14 (0.92–1.40)
 >75 243/1298 1973/13,896 1.34 (1.15–1.55) 1.00 (0.84–1.19)
Drug use  
 PPI 77/361 320/1393 0.96 (0.58–1.58) 0.58 (0.28–1.20)
 No PPI use 407/2249 2898/27,728 1.69 (1.50–1.90) 1.11 (0.96–1.28)
 NSAID 176/884 453/3137 1.27 (0.96–1.66) 0.95 (0.68–1.33)
 No NSAID use 308/1726 2765/25,984 1.76 (1.53–2.01) 1.09 (0.92–1.28)
 Antiplatelet drugs 201/430 849/2,306 1.19 (0.98–1.43) 1.17 (0.93–1.47)
 No use of antiplatelet drugs 443/2,546 3120/28,840 1.65 (1.47–1.84) 1.05 (0.92–1.20)
Medical history  
 No GI cancer 444/2,461 3005/27,805 1.69 (1.51–1.89) 1.06 (0.92–1.21)
 No ulcer antecedents 448/2465 3156/28,748 1.67 (1.49–1.87) 1.05 (0.92–1.20)
 No markers of alcohol abuse 464/2483 3186/28,850 1.69 (1.51–1.89) 1.08 (0.94–1.23)
 Ever use of other antihypertensives 269/698 1639/5491 1.20 (1.00–1.45) 0.99 (0.78–1.25)
Charlson comorbidity index  
 0 228/1477 1975/21,778 1.76 (1.50–2.06) 1.03 (0.85–1.26)
 1–2 138/748 871/5708 1.17 (0.91–1.50) 0.88 (0.64–1.22)
 3 or more 118/385 372/1635 1.68 (1.06–2.65) 1.45 (0.74–2.87)
ASA, acetylsalicylic acid; COPD, chronic obstructive pulmonary disease; DDD: Defined daily doses; HP, Helicobacter 
pylori; NSAID, non-steroidal anti-inflammatory drugs; PPI, proton pump inhibitors; SSRI, selective serotonin reuptake 
inhibitors; UGIB, upper gastrointestinal bleeding; VKA, vitamin K antagonists.
* Adjusted for: current use of: VKA, ASA, other antiplatelet drugs, NSAID, SSRIs, systemic corticosteroids, PPIs, H2 
receptor antagonists, statins, nitrates, spironolactone, calcium antagonists, bisphosphonates; any history of: UGIB, HP 
eradication, peptic ulcer, COPD, diabetes, ischemic heart disease, heart failure, stroke, hypertension, inflammatory 
bowel disease, malignant disease, renal failure; and prescription or diagnosis markers of smoking or excessive alcohol 
consumption.
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factors that may be difficult to account for in reg-
istry data. Second, we did not have data on use of 
ulcerogenic over-the-counter (OTC) drugs, such 
as high-dose aspirin. The prescription coverage of 
low-dose aspirin and NSAIDs was in the order of 
85% and 70% during our study period,40 but there 
is no reason to suspect more OTC drug exposure 
among users of beta-blockers than among others. 
Though of very high quality, our data are some-
what old. However, this allowed us to analyze the 
difference between selective and non-selective 
beta-blockers. The use of non-selective beta-
blockers has decreased substantially in recent 
years,40 and more recent data would thus contrib-
ute little to elucidating the possible effect modifi-
cation by receptor selectivity. In addition, 
antithrombotic use has become increasingly com-
plex and aggressive over recent years,41 thereby 
leaving more room for confounding.
In conclusion, there was no association between 
beta-blocker use and serious UGIB in this large 
population-based study.
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Appendix
Table A1. ATC codes used to define covariates.
ATC code
VKA B01AA
ASA B01AC06 (excl. B01AC30)
Other antiplatelet drugs B01AC (excl. B01AC06)
NSAIDs M01A (excl. M01AX)
SSRI N06AB
Systemic corticosteroids H02AB
PPI A02BC
H2 receptor antagonists A02BA
Statins C10AA
Nitrates C01DA
Spironolactone C03DA01
Calcium antagonists C08
Bisphosphonates M05BA, M05BB
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Table A2. ICD-10 codes used to define covariates.
ICD-10 codes
Stroke I60, I61, I62, I63, I64, I65, I66, I67, I69, G45
Hypertension I10, I11, I12, I13, I15
Inflammatory bowel disease K50, K51, K528C
Malignant disease C (excl. C44, C98), D45, D46, D471, D473, D474, D475
Renal failure E102, E112, E122, E132, E142, I12, N01, N03, N083, N085, N118C, N14, 
N150, N16, N18, N19, N26, P960, Q601, Q602, Z992 (excl. I129 N160 N181)
Alcohol-related diagnoses E244, E529A, F10, G312A, G312B, G312C, G312D, G312E, G405B, G621, 
G721, I426, K292, K70, K860, O354, P043, T519, Z502, Z714, Z721
Tobacco-related diagnoses J40, J41, J42, J43, J44, C34
UGIB K250, K252, K254, K256, K260, K262, K264, K266, K270, K272, K274, K276, 
K280, K282, K284, K286, K290
Peptic ulcers K25, K26, K27, K28
COPD J40, J41, J42, J43, J44
Diabetes E10-14, E145D, E891A, G590, G632, G730A, G990C, H280, H360, I792A, 
M142, N083, O240, O241, O242, O243
Ischemic heart disease I200, I201, I201A, I201B, I208, I208A, I209, I210, I211, I212, I212A, I212B, 
I212C, I212D, I212E, I212F, I212G, I212H, I213, I214, I219, I22, I220, I220A, 
I220B, I220C, I221, I221A, I221B, I221C, I228, I228A, I228B, I228C, I228D, 
I228E, I228F, I228G, I228H, I229, I23, I230, I232, I236, I236A, I236B, I238, 
I241, I252, Z951
Heart failure I110, I42, I50, J819
